Linde R&D increased by 8.6% to $38.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $38.00M to $38.00M. Over 4 years (FY 2021 to FY 2025), R&D shows relatively stable performance with a 0.7% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $34.00M | $36.00M | $38.00M | $35.00M | $37.00M | $35.00M | $36.00M | $36.00M | $35.00M | $36.00M | $39.00M | $38.00M | $36.00M | $37.00M | $39.00M | $38.00M | $38.00M | $36.00M | $35.00M | $38.00M |
| QoQ Change | — | +5.9% | +5.6% | -7.9% | +5.7% | -5.4% | +2.9% | +0.0% | -2.8% | +2.9% | +8.3% | -2.6% | -5.3% | +2.8% | +5.4% | -2.6% | +0.0% | -5.3% | -2.8% | +8.6% |
| YoY Change | — | — | — | — | +8.8% | -2.8% | -5.3% | +2.9% | -5.4% | +2.9% | +8.3% | +5.6% | +2.9% | +2.8% | +0.0% | +0.0% | +5.6% | -2.7% | -10.3% | +0.0% |